|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical Trials, Vol. 3, No. 2,
142-148 (2006)
DOI: 10.1191/1740774506cn137oa
An Institutional Review Board dilemma: responsible for safety monitoring but not in control
David L DeMets
Biostatistics & Medical Informatics, University of Wisconsin, 600 Highland Avenue, USA; demets{at}biostat.wisc.edu
Norman Fost
University of Wisconsin, Madison, WI, USA
Madison Powers
Georgetown University, Washington, DC, USA
Clinical trials have become a major research tool to evaluate new medical interventions. Most trials require some level of data monitoring for quality control and many trials require special monitoring for participant safety. For national multicenter trials, independent data monitoring committees have become the standard for monitoring for evidence of participant benefit or harm in trials with irreversible outcomes such as death or serious morbidity. The Institutional Review Board (IRB) is held responsible for monitoring local trials. Often local institutions do not have an infrastructure in place to meet this responsibility, and therefore local IRBs cannot fulfill this obligation. In addition, IRBs are currently inundated with individual safety reports from local and multi-institutional trials which may appear to provide some level of safety monitoring, but in fact gives a false sense of security. We propose the establishment of institutional data monitoring committees and appropriate informatics infrastructure to monitor local trials.
References
- 1. Steinbrook R. Trial design and patient safety – The debate continues. N Engl J Med 2003; 349: 629–630.[Free Full Text]
- 2. Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA 2001; 285: 1201–1205.[Abstract/Free Full Text]
- 3. Malakoff D. Clinical research. Flawed cancer study leads to shake-up at University of Oklahoma. Science2000; 289: 706–7707.[Free Full Text]
- 4. Weiss R. US halts research on humans at Duke; university can't ensure safety, probers find. Washington Post, 12 May 1999.
- 5. OHRP orders Johns Hopkins University to suspend human subjects research. J Investig Med 2001; 49: 379-3379.[Medline]
[Order article via Infotrieve]
- 6. National Institutes of Health. NIH policy for data and safety monitoring. NIH Guide, retrieved 16 March 2006 from http://grants2.nih.gov/grants/guide/ notice-files/not98-084.html, 1998.
- 7. US Food and Drug Administration. Draft Guidance for Clinical Trial sponsors on the establishment and operation of Clinical Trial Data Monitoring Committees. FDA, from http://www.fda.gov/cber/gdlns/clindatmon.htm,2001.
- 8. Federal Policy for the Protection of Human Subjects. Assuring compliance with this policy – research conducted or supported by any Federal Department or Agency. 56 Federal Register 28003 (Codified at 45 CFR
 46.103(b)(2)), 1991. - 9. Sugarman J. The role of institutional support in protecting human research subjects. Acad Med 2000; 75: 687–692.[ISI][Medline]
[Order article via Infotrieve]
- 10. Burman WJ, Reves RR, Cohn DL, Schooley RT. Breaking the camel's back: Multicenter clinical trials and local institutional review boards. Ann Intern Med 2001; 134: 152–157.[Abstract/Free Full Text]
- 11. Esenstein E, Lemons P, Tardiff B, Schulman K, Jolly M, Califf R. Reducing the costs of phase III cardiovascular trials. Am Heart J 2005; 149: 482–488.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- 12. Califf RM, Morse MA, Wittes J et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24: 256–271.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- 13. Califf RM, Karnash SL, Woodlief LH. Developing systems for cost-effective auditing of clinical trials. Control Clin Trials 1997; 18: 651–660.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- 14. Ellenberg S, Fleming T, DeMets D.Data Monitoring Committees in clinical trials: A practical perspective. John Wiley & Sons, Ltd., 2002.
- 15. Greenberg Report. Organization, review, and administration of cooperative studies. Control Clin Trials 1988; 9: 137–148.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- 16. European Union Directive on Good Clinical Practice in Clinical Trials 2001/20/EC. Official Journal of the European Communities L121: 34–344.
- 17. ICH Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Stat Med 1999; 18: 1905–1142.[ISI][Medline]
[Order article via Infotrieve]
- 18. Fisher B, Anderson S, Redmond C, Wolmark N, Wickerham D, Cronin W. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333: 1456–1161.[Abstract/Free Full Text]
- 19. Office of Human Research Protections. Guidance on continuing review, retrieved 15 December 2005 from http://www.hhs.gov/ohrp/humansubjects/guidance/contrev2002. 11 July 2002.
- 20. Responsible research: A systems approach to protecting research participants. Institute of Medicine, National Academy of Sciences, 2003.
- 21. Mello MM, Studdert DM, Brennan TA. The rise of litigation in human subjects research. Ann Int Med 2003; 139: 40–445.[Abstract/Free Full Text]
- 22. Office for Human Research Protections (OHRP). DRAFT guidance on reporting and reviewing adverse events and unanticipated problems involving risks to subjects or others. 11 October 2005. Retrieved 15 December 2005 from http://www.hhs.gov/ohrp/requests/aerg.html
- 23. Department of Health and Human Services. Protection of human subjects. IRB Review of Research Code of Federal Regulations, Title 45, Vol. 1, Part 46, Section 109 (e). Retrieved 19 December 2005 from http://www.gpoaccess.gov/cfr/retrieve.html
- 24. Department of Health and Human Services. Code of Federal Regulations, Protection of human subjects. Assuring compliance with this policy – research conducted or supported by any Federal Department or Agency. Title 45, Vol. 1, Part 46, Section 103. Retrieved 19 December 2005 from http://www.gpoaccess.gov/cfr/retrieve.html
- 25. From http://www3.cancer.gov/cancercenters/ccsg_competing_index1.html.
- 26. From www.oncore.org.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Cook MD, F. Lauzier MD, M. G. Rocha MD, M. J. Sayles RN, and S. Finfer MD
Serious adverse events in academic critical care research
Can. Med. Assoc. J.,
April 22, 2008;
178(9):
1181 - 1184.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Fost and R. J. Levine
The Dysregulation of Human Subjects Research
JAMA,
November 14, 2007;
298(18):
2196 - 2198.
[Full Text]
[PDF]
|
|
|
|
